-
5 × $199.00 -
3 × $333.00 -
1 × $699.00 -
1 × $149.00 -
1 × $209.00 -
1 × $125.00 -
1 × $436.00 -
1 × $109.00 -
1 × $269.00 -
1 × $165.00 -
3 × $272.00 -
1 × $399.00 -
-
-
1 × $80.00 -
1 × $254.00 -
-
2 × $69.00 -
1 × $369.00 -
2 × $69.00 -
-
1 × $105.00 -
-
1 × $259.00 -
-
2 × $139.00 -
1 × $69.00 -
1 × $119.10 -
1 × $139.00 -
1 × $129.00 -
1 × $19.90 -
1 × $159.00 -
2 × $365.00 -
1 × $997.00 -
1 × $1,398.00 -
2 × $866.00 -
1 × $996.00 -
1 × $167.00 -
1 × $4.20 -
1 × $2.90
-
Luciolap（lynparza）Olaparib 50mg online
in patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Luciolap.
1,399.00 per 112 Tablets
$1,399.00Luciolap（lynparza）Olaparib 50mg online
$1,399.00